Pearl Huang is a venture partner at Flagship Pioneering and chief executive officer of Cygnal Therapeutics, a Flagship Pioneering company. She is also on the board of Cygnal.
Before joining Flagship, Pearl most recently served as senior vice president and global head of therapeutic modalities at Roche, where she oversaw the discovery of biologic, small molecule, and nucleic acid-based therapies. Prior to Roche, Pearl was vice president and global head of discovery academic partnerships at GSK. In 2010, she founded BeiGene and served as chief scientific officer until 2012, developing the company’s initial drug discovery pipeline and moving the company’s first programs into the clinic. From 2006 to 2010, Pearl served as vice president, oncology integrator, discovery and early development at Merck, leading 14 early development teams and conducting seven first-in-human trials in one year. Prior to that, she led oncology discovery at GSK, initiating the programs that delivered tramentinib and dabrafenib to patients.
Pearl received her undergraduate degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular biology from Princeton University.